Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum

Peptides

Volumn 21, Issue 8, 2000, Pages 1257-1264

  Minshall, Richard D ^b   Nedumgottil, Sumol J ^a   Igić, Rajko ^a   Erdös, Ervin G ^b   Rabito, Sara F ^a  

^a Jr Hospital of Cook County   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

ACE inhibitors; Bradykinin B2 receptor; Cathepsin G; Chymotrypsin; Kininase II; Potentiation; Sensitization

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR; CATHEPSIN G; CHYMOTRYPSIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; HISTAMINE; ICATIBANT; KININ; QUINAPRIL; QUINAPRILAT; RAMIPRIL; RAMIPRILAT;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; GUINEA PIG; HYDROLYSIS; ILEUM CONTRACTION; MUSCLE ISOTONIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEPTOR SENSITIVITY;

ANIMALS; BRADYKININ; CATHEPSINS; CHYMOTRYPSIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENALAPRILAT; GUINEA PIGS; HYDROLYSIS; ILEUM; PEPTIDYL-DIPEPTIDASE A; RADIOIMMUNOASSAY; RECEPTORS, BRADYKININ; SERINE ENDOPEPTIDASES;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0033785734     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(00)00267-9     Document Type: Article

References (51)

1. Auch-Schwelk W., Bossaller C., Claus M., Graf K., Gräfe M., Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res. 27:1993;312-317.
2. Carretero O.A., Oza N.B., Piwonska A., Ocholik T., Scicli O.G. Measurement of urinary kallikrein activity by kinin radioimmunoassay. Biochem Pharmacol. 25:1976;2265-2270.
3. Carretero OA, Scicli AG. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In: Laragh JH; Brenner BM, editors. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven Press, 1995:983-99.
4. Chi C.W., Wang S.Z., Xu L.G., Wang M.Y., Lo S.S., Huang W.D. Structure-function studies on the bradykinin potentiating peptide from Chinese snake venom (Agkistrodon halys Pallas). Peptides. 6:1985;339-342.
5. Corvol P., Williams T.A. Peptidyl-dipeptidase A/angiotensin I-converting enzyme. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. 1998;1066-1076 Academic Press, San Diego.
6. Deddish P.A., Marcic B., Jackman H.L., Wang H.-Z., Skidgel R.A., Erdös E.G. N-Domain specific substrate and C-domain inhibitors of angiotensin-converting enzyme. Angiotensin-(1-7) and keto-ACE. Hypertension. 31:1998;912-917.
7. Deddish P.A., Wang J., Michel B., Morris P.W., Davidson N.O., Skidgel R.A., Erdös E.G. Naturally occurring active N-domain of human angiotensin I-converting enzyme. Proc Natl Acad Sci. 91:1994;7807-7811.
8. Edery H. Further studies on the sensitization of smooth muscle to the action of plasma kinins by proteolytic enzymes. Br J Pharmacol. 24:1965;485-496.
9. Edery H. Potentiation of the action of bradykinin on smooth muscle by chymotrypsin, chymotrypsinogen and trypsin. Br J Pharmacol. 22:1964;371-379.
10. Erdös E.G. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension. 16:1990;363-370.
11. Erdös EG. Kininases. In. Erdös EG, editor. Bradykinin, Kallidin and Kallikrein. Handbook of Experimental Pharmacology, supplement to vol XXV. Heidelberg: Springer-Verlag; 1979:427-448.
12. Erdös E.G., Deddish P.A., Marcic B.M. Potentiation of bradykinin actions by ACE inhibitors. Trends Endocrinol Metab. 10:1999;223-229.
13. Erdös E.G., Jackman V., Barnes W.C. Instrument for recording isotonic contractions of smooth muscles. J Applied Physiol. 17:1962;367-369.
14. Erdös E.G., Sloane E.M. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol. 11:1962;585-592.
15. Erdös E.G., Yang H.Y.T. Inactivation and potentiation of the effects of bradykinin. Erdös E.G., Back N., Sicuteri F. Hypotensive Peptides. 1966;235-250 Springer-Verlag, New York.
16. Erdös E.G., Wohler J.R. Inhibition in vivo of the enzymatic inactivation of bradykinin and kallidin. Biochem Pharmacol. 12:1963;1193-1199.
17. Ferreira S.H. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol. 24:1965;163-169.
18. Ferreira S.H., Rocha e Silva M. Potentiation of bradykinin and eledoisin by BPF (Bradykinin Potentiating Factor) from Bothrops jararaca venom. Experientia. 21:1965;347-349.
19. Gavras H.G., Faxon D.P., Berkoben H.R., Ryan T.J. Angiotensin converting enzyme inhibition in patients with heart failure. Circulation. 58:1978;770-776.
20. Johnson A.R., Erdös E.G. Metabolism of vasoactive peptides by human endothelial cells in culture angiotensin I converting enzyme (kininase II) and angiotensinase . J Clin Invest. 59:1977;684-695.
21. Johnson A.R., Erdös E.G. Release of histamine from mast cells by vasoactive peptides. Proc Soc Exp Biol Med. 142:1973;1252-1256.
22. Khairallah P.A., Page I.H. Effects of bradykinin and angiotensin on smooth muscle. Ann NY Acad Sci. 104:1963;212-221.
23. Lewis E.J., Hunsicker L.G., Bain R.P., Hohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
24. Linz W., Wiemer G., Gohlke P., Unger T., Schölkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49.
25. 2 receptor. Hypertension. 33:1999;835-843.
26. Marcic B., Deddish P.A., Jackman H.L., Erdös E.G., Tan F. Effects of the N-terminal sequence in the N-domain of ACE on the properties of its C-domain. Hypertension. 36:2000;116-121.
27. 2 bradykinin receptor by ACE inhibitors. J Biol Chem. 275:2000;16110-16118.
28. Minshall R.D., Erdös E.G., Vogel S.V. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol. 80:1997;132A-136A.
29. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 81:1997;848-856.
30. Odya C.E., Levin Y., Erdös E.G., Robinson C.J.G. Soluble dextran complexes of kallikrein, bradykinin, and enzyme inhibitors. Biochem Pharmacol. 27:1978;173-179.
31. Ondetti M.A. From peptides to peptidases a chronicle of drug discovery . Ann Rev Pharmacol. 34:1994;1-16.
32. Ondetti M.A., Williams N.J., Sabo E.F., Pluscec J., Weaver E.R., Kocy O. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry. 10:1971;4033-4039.
33. Osbahr A.J., Gladner J.A., Laki K. Studies on the physiological activity of peptides released during the fibrinogen-fibrin conversion. Biochim Biophys Acta. 86:1964;535-542.
34. Pfeffer J.M., Fischer T.A., Pfeffer M.A. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu Rev Physiol. 57:1995;805-826.
35. Reilly C.F., Schechter N.B., Travis J. Inactivation of bradykinin and kallidin by cathepsin G and mast cell chymase. Biochem Biophys Res Com. 127:1985;443-449.
36. Rocha e Silva M. The physiological significance of bradykinin. Ann NY Acad Sci. 104:1963;190-211.
37. Rubin B., Laffan R.J., Kotler D.G., O'Keefe E.H., Demaio D.A., Goldberg M.E. SQ 14,225 (D-3-mercapto-2-methylpropanoyl-L-proline), a novel orally active inhibitor of angiotensin I-converting enzyme. J Pharmacol Exp Ther. 204:1978;271-280.
38. Schölkens B.A., Linz W., König W. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischemic rat heart are abolished by a bradykinin antagonist. J Hyperten. 6:(suppl 4):1988;S25-S28.
39. Skidgel RA, Erdös EG. Biochemistry of angiotensin I converting enzyme. In: Robertson, JIF; Nicholls MG, editors. The Renin-Angiotensin System, Vol 1. London: Gower Medical Publishing, 1993;10:1-10.10.
40. Skidgel R.A., Jackman H.L., Erdös E.G. Metabolism of substance P and bradykinin by human neutrophils. Biochem Pharmacol. 41:1991;1335-1344.
41. Stewart M.J., Ferreira S.H., Greene L.J. Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro - an inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II. Biochem Pharmacol. 20:1971;1557-1567.
42. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risks patients. N Engl J Med. 342:2000;145-153.
43. Ufkes J.G.R., Aarsen P.N., van der Meer C. The bradykinin potentiating activity of two pentapeptides on various smooth muscle preparations. Eur J Pharmacol. 40:1976;137-144.
44. Ufkes J.G.R., Aarsen P.N., van der Meer C. The mechanism of action of two bradykinin-potentiating peptides on isolated smooth muscle. Eur J Pharmacol. 44:1977;89-97.
45. Vogel V.R., Werle E., Zickgraf-Rüdel C. Neuere Aspekte der Kininforschung. I. Potenzierung und Blockierung der biologischen Kininwirkung. Z Klin Chem u Klin Biochem. 8:1970;177-185.
46. von Euler U.S. Substance P in subcellular particles in peripheral nerves. Ann NY Acad Sci. 104:1963;449-463.
47. Werle E., Grunz M. Zur Kenntnis der darmkontrahierenden, uteruserregenden und blutdrucksenkenden Substanz DK. Biochem Z. 301:1939;429-436.
48. Werle E., Trautschold I. Kallikrein, kallidin, kallikrein inhibitors. Ann NY Acad Sci. 104:1963;117-129.
49. Yang H.Y.T., Erdös E.G. Second kininase in human blood plasma. Nature. 215:1967;1402-1403.
50. Yang H.Y.T., Erdös E.G., Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 214:1970;374-376.
51. Yang H.Y.T., Erdös E.G., Levin Y. Characterization of a dipeptide hydrolase (kininase II; angiotensin I converting enzyme). J Pharmacol Exp Ther. 177:1971;291-300.